BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Almirall and Barcelona Supercomputing Center expand collaboration to accelerate innovation in medical dermatology

April 13, 2026 | News

Leveraging Artificial Intelligence and High-Performance Computing



Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, has announced an expanded collaboration with the Barcelona Supercomputing Center – Centro Nacional de Supercomputación (BSC – CNS). This new framework agreement strengthens their partnership, aiming to accelerate research and development in medical dermatology by applying advanced supercomputing, High-Performance Computing (HPC), and Artificial Intelligence.

The collaboration is a testament to Almirall's commitment to pushing the boundaries of science to address the needs of patients with skin conditions. It builds on previous successful R&D joint projects and is framed within the broader research collaboration between BSC and Almirall. The partnership is a key pillar of Almirall's innovation strategy, which focuses on leveraging cutting-edge technology and collaborative ecosystems to develop novel treatments.

As part of the enhanced partnership, Almirall will join 'BSC Connects', a strategic initiative launched by BSC designed to bridge advanced scientific knowledge with industry leaders. Participation in this program will provide Almirall with access to personalized training, cutting-edge technologies, and tailored support for co-developing innovative R&D projects throughout 2026. This will enable Almirall to further integrate disruptive technologies throughout its R&D pipeline and development processes, ultimately benefiting patients.

By capitalising on the scientific talent of BSC and Almirall, the BSC Connect collaboration framework will drive the identification of innovative technologies with high-impact potential and provide an opportunity to establish direct collaboration on scientific topics of mutual interest, ranging from genomics to digital twins and drug design.